In addition to its potential as a basal biomarker of oxaliplatin response, studies in colorectal and ovarian cancer cells have demonstrated that ERCC1 expression is induced upon treatment with platinum-based agents [25], while work from our group has demonstrated that the extent of ERCC1 induction in CRC cell lines treated with oxaliplatin, can distinguish sensitive from resistant cell lines [26]. The gene discussed is ERCC1; the disease is colorectal carcinoma.